Olaparib + Usual Chemotherapy (Temozolomide) in PPGL << Back Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer CLINICALTRIALS.GOV IDENTIFIER: NCT04394858 DRUG/TREATMENT: Olaparib and Temozolomide PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=OuLlxvYXYHI Dr. Jaydira Del Rivero Discusses TMZ vs TMZ Olaparib DESCRIPTION: This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. PRINCIPAL INVESTIGATOR: Jaydira Del Rivero, MD Alliance for Clinical Trials in Oncology

Join NCF for NCD2025_Speakers. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page Back to NCD Symposium Page 2025 NET Cancer Day Symposium Speakers Taymeyah Al-Toubah, MPH, CCRP FlaNET, Medical Student I hold dual bachelor’s degrees in Biomedical Sciences and Psychology (2015) and a Master of Public Health in Epidemiology (2017). Since 2013, I have worked in academic medicine and clinical research, beginning with neonatology and pediatrics before transitioning to phase I oncology in 2016. My interest in neuroendocrine tumors (NETs) began during my MPH thesis, which became one of my first NET publications. From 2018–2023, I served as the primary NET coordinator at Moffitt Cancer Center, managing all clinical trials, leading the GI team, and driving retrospective and non-interventional research. In 2023, I transitioned to Senior Project Manager of the NET program, overseeing protocol development, database creation, and manuscript writing, while curating a master database of more than 10,000 NET patients. After nearly a decade at Moffitt, I concluded my tenure in September 2025 to begin medical school in Italy the following month. I have published more than 45 manuscripts and delivered oral presentations at both ENETS and NANETS. Beyond institutional research, I serve on the Board of Directors of NANETS (now in my second year) and on the board of FLaNET Carcinoid Community. I also actively mentor three students in neuroendocrine tumor research: two undergraduate pre-medical students and a high school prodigy pursuing mathematical oncology and AI. In July 2025, I launched TayTalks , a podcast exploring professional growth, medicine, and life. Looking ahead, I am eager to combine my research foundation, medical training, and passion for advocacy to advance the care of NET patients as a future physician-scientist. Aman Chauhan, MD Medical Oncologist Sylvester Comprehensive Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. Tracy Crane, PhD, RDN Medical Oncology Sylvester Cancer Center Dr. Tracy E. Crane is an internationally recognized thought leader in cancer prevention and control, specializing in digital health interventions to improve patient outcomes. She is an Associate Professor of Medical Oncology, Public Health, and Kinesiology at the University of Miami and Co-Leader of the Cancer Control Research Program at Sylvester Comprehensive Cancer Center. As Director of Lifestyle Medicine, Prevention, and Digital Health, she leads a multidisciplinary research team focused on innovative lifestyle interventions, leveraging AI-driven technology to deliver precision behavioral strategies. In the last 5 years, she has secured over $30 million in research funding, including multiple National Cancer Institute (NCI)-funded studies and a large PCORI-funded trial, and has authored over 100 peer-reviewed publications, including co-authoring the latest American Cancer Society guidelines on nutrition and physical activity for cancer survivors. A registered dietitian with a Ph.D. in Nursing Science, Dr. Crane also serves as Chair for Cancer Prevention and Control nationally for NRG Oncology’s NCI Community Oncology Research Program. Her pioneering contributions have made her a sought-after speaker and leader in the global effort to integrate digital health and personalized lifestyle medicine into cancer prevention and care. Jashodeep Datta, MD Surgical Oncologist Sylvester Comprehensive Cancer Center Dr. Datta is the DiMare Family Endowed Chair in Immunotherapy, Associate Professor of Surgery, and a hepatobiliary and pancreatic surgical oncologist at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center. He is also a surgeon-scientist studying myeloid immunobiology in the pancreatic cancer microenvironment and novel ways to deploy immunotherapy in this disease. At Sylvester, he serves as the Assistant Director of Transdisciplinary Research, and Co-Leader of the Gastrointestinal Oncology Service Line at Sylvester where his mission is to augment the portfolio of investigator-initiated clinical trials offered in GI cancers. He is also the Associate Director of Translational Research at the Sylvester Pancreatic Cancer Research Institute. Dr. Datta joined the faculty at the University of Miami Miller School of Medicine in 2019. He graduated Summa cum Laude from Colgate University in Hamilton, NY and attended Vanderbilt University School of Medicine in Nashville, TN where he earned his MD and was inducted in the Alpha Omega Alpha (AOA) National Honor Society. He completed his residency in General Surgery at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA, during which he completed a post-doctoral research fellowship in cancer immunology. He subsequently completed a fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center, where he focused on surgical management of hepatobiliary, pancreatic, and gastric malignancies and developed expertise in computational immunogenomics. Since starting at Sylvester, his research has been extensively funded by the Miami Clinical and Translational Science Institute with an NIH KL2 award, American College of Surgeons’ Franklin H. Martin Research Fellowship, Association for Academic Surgery Joel J. Roslyn Faculty Award, Society for Surgical Oncology Young Investigator Award, the Elsa U. Pardee Foundation, the Pancreatic Cancer Action Network Career Development Award, the Department of Defense Pancreatic Cancer Research Program (PCARP), the V Foundation for Cancer Research, and the National Cancer Institute. His work has been recognized by multiple awards, including the Joan L and Julius H Jacobson II Promising Investigator Award from the American College of Surgeons, and an American Society of Clinical Investigation Young-Physician Scientist Award. Udhayvir Singh Grewal, MD Medical Oncologist Emory University School of Medicine Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. Boris Naraev, MD, PhD, FACP Medical Oncologist Tampa General Hospital Cancer Institute Dr. Naraev is a board-certified medical oncologist at the Tampa General Hospital’s Cancer Institute specializing in caring for people living with neuroendocrine and endocrine tumors. He is an Associate Professor of Medicine at the Division of Hematology and Medical Oncology of University of South Florida, Morsani College of Medicine. Prior to joining the TGH Cancer Institute, he was the Lead of Neuroendocrine Cancer Program at Banner MD Anderson Cancer Center in Phoenix, Arizona and Adjunct Assistant Professor with the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. While in Phoenix, he helped create, develop, and lead one of the largest neuroendocrine cancer programs in the Southwestern United States, and was personally taking care of a large population of patients with neuroendocrine tumors. Later, he served as the Leader of Gastrointestinal, Neuroendocrine, and Rare Cancers Program at the Anderson Family Cancer Institute at Jupiter Medical Center in Jupiter, Florida. In this capacity, he helped build the National Pancreas Foundation Pancreatic Cancer Center of Excellence at Jupiter Medical Center. He received his Doctor of Medicine degree from Orenburg State Medical Academy in Orenburg, Russia. Subsequently, he obtained PhD in Medical Sciences degree from the same institution. After completion of Internal Medicine residency training at St. Luke's Hospital in Chesterfield, Missouri, he proceeded to complete Hematology/Oncology Fellowship at the University of Iowa Hospitals and Clinics in Iowa City, Iowa. During his fellowship training, he developed a special interest in neuroendocrine tumors and completed several research projects in this field. Dr. Naraev is involved in neuroendocrine tumors related research and community outreach, and is a member of the NETPact Committee and Co-Chair of Guidelines Committee of the North American Neuroendocrine Tumor Society. Estelamari Rodriquez, MD, MPH Clinical Research Lead Thoracic Site Disease Group Associate Director for Community Outreach Sylvester Cancer Center Dr. Estelamari Rodriguez is Co-Lead of the Thoracic Site Disease Group and Associate Director of Community Outreach and of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is an active member of the Sylvester Experimental Therapeutics Program and has served as principal investigator of several early phase and cooperative group clinical trials in the United States. Dr. Rodriguez is a member of the ECOG Thoracic Committee and Chair-elect of the ASCO Evidence Based Medicine Committee. She has active advocacy roles as part of the board of the American Cancer Society- Cancer Action Network, the Miami Dade County Medical Association and Florida Society of Clinical Oncology (FLASCO). Dr. Rodriguez received her bachelor's degree from Columbia College and her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University’s New York-Presbyterian Hospital and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master’s degree in Public Health from the Universidad Autonoma de Madrid, Spain. She has given numerous international lectures as an invited speaker on issues related to lung cancer treatment and healthcare disparities. Jason Starr, DO Hematologist / Oncologist Mayo Clinic Dr. Starr grew up in South Florida and earned his medical degree at Lake Erie College of Osteopathic Medicine in Bradenton, Florida. He did his training at Mayo Clinic School of Graduate Medical Education in Jacksonville, where he completed his internship and residency in internal medicine, followed by a hematology/oncology fellowship. Dr. Starr has developed an expertise in treating gastrointestinal malignancies and has co-authored papers and book chapters on the subject. He has a special interest in neuroendocrine tumors and is committed to advancing the field through clinical research, namely through the development and enrollment of clinical trials. Dr. Starr is also passionate about education and is integrally involved with fellow education and well-being. He is board certified in internal medicine, hematology, and oncology. "The greatest joy of my career is the interaction and relationships I am able to have with my patients," says Dr. Starr. In his free time he enjoys and values spending time with his wife and children. He also enjoys exercise for fitness and stress relief. Dr. Starr is proud of his Mayo roots and feels strongly about Mayo Clinic's conviction to hope, faith, and science. Lindsay Thornton, MD Interventional Radiologist Sylvester Cancer Center Dr. Lindsay Thornton, M.D., is an Assistant Professor of Clinical Interventional Radiology at the University of Miami Miller School of Medicine. She specializes in interventional oncology, with a focus on hepatocellular carcinoma (HCC), metastatic colorectal cancer, neuroendocrine cancer, and uveal melanoma. She is highly skilled in transradial techniques for liver cancer treatments, uterine fibroid therapy, and other intra-arterial procedures. Dr. Thornton earned her medical degree from the University of Vermont, followed by an Internal Medicine internship at Rutgers-University Hospital. She then completed her Diagnostic Radiology residency at the University of Florida, where she served as Chief Resident of Research. She also was elected Clinical Education Chair for the Society of Interventional Radiology’s (SIR) RFS section from 2016-2017. She received the Excellence in Interventional Radiology Award in 2018 from UF and went on to complete her fellowship in Vascular and Interventional Radiology at Mount Sinai Icahn School of Medicine in 2019. She is board-certified in both Diagnostic and Interventional Radiology. Passionate about the disease process and treatment of HCC and clinical research, Dr. Thornton primarily studies locoregional therapies for HCC and co-chairs the Hepatocellular Operations Working Group with Dr. Patricia Jones since 2019. She has published in peer-reviewed journals and presented at national conferences. She also serves on the Interventional Oncology Service Line Committee for SIR (2023-current). An ardent advocate for quality, safety, and process improvement, Dr. Thornton is committed to enhancing patient care and streamlining clinical workflows. Her joy as a physician stems from ensuring high quality, personal care. She has served as Director of Quality, Safety, and Operations in Interventional Radiology at Jackson Memorial Hospital for the past three years. In 2023 she received the UM/JHS Quality and Safety Faculty Showcase Award. Back to NCD Symposium Page

<< Go Back to NCF Events Page "LUNCHEON WITH THE EXPERTS" With Dr. J. Randolph Hecht “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — in neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join during their lunch break. Live sessions are recorded and will be available afterward. ABOUT J. RANDOLPH (RANDY) HECHT, MD Gastrointestinal Medical Oncologist UCLA Health J. Randolph (Randy) Hecht, MD is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. He graduated from Eastern Virginia Medical School and took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. He is the director of the UCLA GI Oncology Program which has one of the largest clinical and research programs in the Western United States. Dr. Hecht is an internationally known clinical and translational researcher who has published widely in the field of gastrointestinal cancers. He has run multiple phase II and phase III trials with targeted therapies and immunotherapy. Dr. Hecht is currently leading national and international multicenter trials with novel immune and CAR-T therapies. Dr. Hecht has a longstanding interest in caring for neuroendocrine tumor patients and runs the multidisciplinary GI NET Clinical Conference. Dr. Randy Hecht is the Medical Director of the University of California Los Angeles (UCLA) GI Neuroendocrine Tumor Program. UCLA is one of the largest major centers for the treatment of neuroendocrine tumors in the western US. He has been the institutional principal investigator for multiple trials in neuroendocrine tumors including studies with novel somatostatin analogues, small molecules, DLL3 directed therapies and immunotherapies as well as the UC Pancreatic Neuroendocrine Neoplasm observational trial. Dr. Hecht works closely with his colleagues in nuclear medicine and has been the medical principal investigator for nuclear medicine trials with lutetium-177 and actinium-225 based therapies. He is also on the medical advisory council of the Neuroendocrine Cancer Foundation, one of the largest NET patient advocacy groups in the world, and serves on the Steering Committee for the development of the NANETS clinical practice guidelines on “Systemic Therapies for Midgut Neuroendocrine Tumors.” HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

<< Go back to the Podcast page EPISODE 4: NET BASICS Download a Transcript of this Episode >> ABOUT THIS EPISODE Newly diagnosed? Or need to brush up on your NET basics? Medical oncologist and NET expert Dr. Andrew Hendifar of Cedars-Sinai Medical Center addresses 10 common questions including labs, scans, genetic testing, and prognosis. MEET DR. ANDREW HENDIFAR The current research focus of Andrew Hendifar, MD , is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves on the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars Sinai he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. TOP 10 NET BASICS QUESTIONS 1. I’ve just been diagnosed with NET. What do I need to know? (3:45) 2. What do I do now? (4:53) 3. What causes NET? (Did I do anything to cause it? Does stress cause NET?) What makes NET tumors grow or spread? (7:40) 4. Is it genetic/should I have genetic testing? Do my family members need to get screened or tested for NET? (12:34) 5. How long do I have? (15:55) 6. How do I know if my tumors are growing or spreading? (20:19) 7. What labs do I need to have and how often? What tumor markers should I be getting? What does it mean if my Chromogranin A is high? (26:00) 8. What scans do I need to have and how often? Should I be getting a CT scan or MRI? What’s the difference? (29:37) 9. How do I know if my tumors are functional or nonfunctional? (33:17) 10. How can we as patients or caregivers help YOU as our NET oncologist make the appointment go better (or help you do your job better)? (41:24) 11. *Bonus: How might I prepare for the appointment? What’s the best way to communicate? (43:35) ADDITIONAL NET BASICS RESOURCES NET VITALS LACNETS Newly Diagnosed Information & Resources https://www.youtube.com/watch?v=r2NKM35a46I NETS 101 - Dr. Sandy Kotiah https://www.youtube.com/watch?list=PLPAgUIq-85n-RDzmx4FMlnn767YTicsHI&v=MLYx_vY4PV0 "What to Expect with a NET Expert Consultation" with Dr. Heloisa Soares https://www.youtube.com/watch?list=PLPAgUIq-85n9pZE-B5NadOH0Znb1rfjPR&v=q9bgkYB6A7w "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (Spanish) https://www.youtube.com/watch?list=PLPAgUIq-85n9pZE-B5NadOH0Znb1rfjPR&v=fCxxPvBM3Eo "Manejo Sintomatico de los Tumores Neuroedocrinos Funcionales" - Dr. Jaydira Del Rivero (Spanish) https://www.youtube.com/watch?list=PLPAgUIq-85n-RDzmx4FMlnn767YTicsHI&v=WA02D1F48sg "Symptom Management" with Dr. Jaydira Del Rivero DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 51 - Highlights of the 2025 NANETS Symposium Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special annual episode, OHSU medical oncologist Dr. Guillaume (“Will”) Pegna joins us once again to break down the highlights from the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. He walks us through the latest clinical trial results and emerging research—covering PRRT, non-PRRT therapies, liver-directed treatments, and new biomarkers—and explains what these updates mean for the NET patient and caregiver community. MEET DR. WILL PEGNA Dr. Pegna is a medical oncologist who specializes in the care of adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas as well as other gastrointestinal cancers. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys. Highlights of the 2025 NANETS Symposium: Clinical Trial Definitions See also Glossary: Common Terms in Clinical Trials Objective Response Rate (ORR) or Response Rate The percentage of patients whose tumors shrink by a meaningful amount after treatment. Progression-Free Survival (PFS) The average length of time patients live without their cancer growing or worsening after starting treatment. Overall Survival (OS) The average length of time patients are alive after starting a treatment, regardless of whether the cancer grows. Disease Control Rate (DCR) The percentage of patients whose cancer is controlled by treatment, including those whose tumors shrink as well as those whose disease remains stable and does not grow. Adverse Events (AEs) Side effects that occur during or after treatment. Grade 3, 4, 5 are the concerning ones. View the abstracts in the 2025 NANETS Symposium Abstract Booklet PRRT Capdevila J, et al. Efficacy of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase 3 COMPETE trial. Abstract C-14 Strosberg J, et al. Long-term Follow-up of PRRT-Naïve Patients with GEP- NETs Treated with Targeted Alpha Therapy 212Pb- DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial. Abstract C-15 ( Presented by Mary Maluccio.) Strosberg J, et al. Phase 2 Study of Targeted Alpha Therapy 212Pb-DOTAMTATE in Patients with Advanced Gastroenteropancreatic (GEP)-NETs Previously Treated with PRRT. Abstract C-16 Chauhan A, et al. Efficacy and Safety of Peptide Receptor Radionuclide Therapy Retreatment (r-PRRT) Practices in Progressive Neuroendocrine Tumors (prog-NETs): Systematic Review and Meta-Analysis. Abstract C-27 * Check out the ongoing NET RETREAT Study in the NCF Clinical Trials Guide THERAPEUTICS SECTION (NON-PRRT) Chauhan A, et al. DAREON®-7: Phase I open-label dose-escalation/- expansion study of first-line obrixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomas . Abstract C-8 . Capdevila J, et al. An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression. Abstract C-1 . * Check out the ongoing DAREON®-7 Clinical Trial and the DAREON®-5 Clinical Trial Sahwan O, et al. The Efficacy of Low-dose vs Standard-dose Everolimus in Patients with Advanced Neuroendocrine Tumors. Abstract C-10. LOCAL REGIONAL THERAPIES Soulen M, et al. Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET). Abstract C-12. Kim J, et al. Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease. Abstract C-25. ( Presented by Nicholas Fidelman.) Wornow, S, et al. Resection of Primary Pancreatic Neuroendocrine Tumors in the Metastatic Setting. Abstract C-44. BIOMARKERS Fu S, et al. Claudin 18.2 in pancreatic neuroendocrine tumors: a potential therapeutic target. Abstract B-13. ( Presented by Garima Gupta.) Singh A, et al. PPM1D as a Potential Driver of Myeloid Malignancy Transformation in Neuroendocrine Tumor (NET) Pts: An Underrecognized Malignant CHIPerpetrator? Abstract C-5. Bendjennat M, et al. Validation of Adversity-Linked Genes in Pancreatic Neuroendocrine Tumors. Abstract B-2. (Presented by Andrea Gillis.) HONORABLE MENTIONS Dillon JS. Clinical integration of GLP-1 into patient care: Risks and clinical integration (MEN1, diabetes, syndromic patients, etc.). Oral presentation at the 2025 NANETS Annual Symposium. Related peer-reviewed article: Shilyansky JS, Chan CJ, Xiao S, et al. GLP-1 receptor agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors. Surgery. 2025. PMID: 39665969. * Check out the NCF podcast episode 49 where Dr. Dillon addresses GLP-1 drugs in NETs Hallet J, et al. Care of Neuroendocrine Tumors: The Collaborative of Surgical Teams for NeuroEndocrine Tumors (CUTNETs). Abstract C-35. Understanding Carcinoid Crisis with Dr. Julie Hallet. 2024 LACNETS (now NCF) Patient Conference What Matters About Liver Surgery with Dr. Julie Hallet. 2025 NCF Patient Conference NANETS The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 11 presentations from the 2025 NANETS Symposium, there are many more noteworthy abstracts found (or listed) here: NANETS Abstract Library 2025 NANETS Abstracts Booklet While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers. RESOURCES Top 10 Highlights of the 2024 NANETS Symposium Top 10 Highlights of the 2023 NANETS Symposium Top 10 Highlights of the 2022 NANETS Symposium Podcast Episode 48: NEN TREATMENTS: FOCUS ON DLL3 Explore the NCF Clinical Trials Guide including study information, videos and resources. DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism << Back upLIFT: A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (Tumor HI) IDENTIFIER ( ClinicalTrials.gov ) : NCT06881992 DRUG/TREATMENT : Ersodetug PHASE : 3 STATUS : Recruiting SPONSOR : Rezolute DESCRIPTION: upLIFT Study Interim Update June 2, 2026 Rezolute has shared an interim update from the upLIFT clinical trial, which is studying an investigational therapy called ersodetug for people with Tumor Hyperinsulinism (Tumor HI). The study is now halfway through enrollment, with 8 of a planned 16 participants enrolled. Of those 8 participants, 6 have met the study's primary endpoint — a reduction of at least 50% in the intravenous (IV) glucose needed to maintain stable blood sugar levels. All 6 were also able to discontinue IV glucose entirely while receiving ersodetug. No drug-related side effects have been reported to date. Participants who complete the initial 8-week treatment period have the option to continue in a 6-month extended phase. Full topline results from the completed study are expected in the second half of 2026. Please note: ersodetug is an investigational therapy that has not yet been reviewed or approved by any regulatory health authority. Read the full press release here. Rezolute is a late-stage rare disease company focused on substantially improving the quality of life for individuals living with hyperinsulinism (HI) and is now enrolling participants in the upLIFT study, a phase 3 clinical trial that is testing whether or not a new therapy, called ersodetug , can safely reduce hypoglycemia in adults with tumor HI. In tumor HI, certain tumors (lumps or abnormal cell growths) in the pancreas or other parts of the body make too much insulin or a similar protein called insulin-like growth factor-2 (IGF-2). Insulinomas are a rare type of neuroendocrine tumor that usually form from the insulin-secreting cells in the pancreas. Non-islet cell tumor hypoglycemia (sometimes called “Doege-Potter syndrome” or “paraneoplastic hypoglycemia”) is a rare condition where certain tumors outside the pancreas make too much hormone growth factors that can act like insulin. Both types of tumors can lead to very low blood sugar levels, a severe and potentially life-threatening complication of overactivation of the insulin receptor. Hypoglycemia can result in neurologic and cognitive problems as well as other serious health complications and may make it hard for people with tumor HI to stay healthy enough to continue their cancer treatments. We know that patients facing these complications often have complex needs and limited treatment options. We believe collaboration between patient advocacy organizations is essential to ensure patients receive the best possible support and access to care. This study is open to people 18 and older who have a type of tumor that causes tumor HI and are still experiencing frequent, serious low blood sugar levels, even with standard treatment. To learn more about the study or potential participation please talk to your doctor or visit upliftstudy.com or clinicaltrials.gov . You may also contact patient affairs via email at patient-affairs@rezolutebio.com for further assistance, if needed. Please note that ersodetug is still under investigation and has not been approved by any health authority. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Name: Rezolute Clinical Trial Phone Number: 650-206-4507 Email: patient-affairs@rezolutebio.com (primary contact). You may also reach out to clinicaltrials@rezolutebio.com . This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. RELATED RESOURCES CancerHypoglycemia.com This is a valuable resource for physicians as we continue to build educational content in non-islet cell tumor hypoglycemia (NICTH). Key elements of the site focus on: Pathophysiology Presentation and diagnosis Limitations in current management The impact of living with NICTH Resources and FAQs

Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms << Back Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms IDENTIFIER ( ClinicalTrials.gov ) : NCT06788938 DRUG/TREATMENT : Tarlatamab PHASE : 2 STATUS : Recruiting SPONSOR : Jonsson Comprehensive Cancer Center https://www.youtube.com/watch?v=HJCZzlD_kq8 Watch Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). DESCRIPTION: This is a Phase II, multi-center “basket” study testing a medication called tarlatamab in people with advanced cancers that show a marker called DLL3. DLL3 is a protein found on the surface of some neuroendocrine and other hard-to-treat tumors. What is Tarlatamab? Tarlatamab is an anti-cancer therapy that helps the immune system find and attack cancer cells. It is already FDA-approved for extensive-stage small cell lung cancer, but its use in other tumors is still considered investigational, meaning researchers are studying how well it works and how safe it is for these additional cancer types. About the Study This trial is being done to learn: How well tarlatamab works in treating DLL3-positive cancers What side effects it may cause How safe and tolerable the treatment is in different types of tumors The study is enrolling people with advanced DLL3-expressing tumors other than small cell lung cancer or neuroendocrine prostate cancer. Participants will receive tarlatamab as long as it is helping and side effects remain manageable. Treatment will continue until the cancer grows, side effects become unacceptable, the patient chooses to stop, or another medical reason requires stopping. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here . CONTACT Contact: CRU Hotline Phone Number: 888-798-0719 Email: istteam@mednet.ucla.edu Study Contact Backup Name: CRU Direct line Phone Number: 310-206-2632 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Join NCF for Feb2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=DcewKhYm8uY Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis, at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. ABOUT DR. ALLEN LUIS Dr. S. Allen Luis, MD, Ph.D, is the Associate Dean for Student and Faculty Affairs at the Mayo Clinic School of Health Sciences and the Associate Chair for Education for the Department of Cardiovascular Diseases. He also serves as Medical Director for the Mayo Clinic School of Health Sciences Echocardiography and Advanced Cardiovascular Sonography Programs. He works in the Carcinoid Heart Disease Clinic, is Co-director of the Pericardial Diseases Clinic and is an Associate Professor of Medicine at Mayo Clinic (Rochester, Minnesota). Dr. Luis is an Associate Editor for Frontiers in Cardiovascular Medicine and a member of the American Journal of Cardiology Editorial Board. He serves on the Board of Directors for the American College of Cardiology (Minnesota Chapter) and the Committee on Accreditation for Advanced Cardiovascular Sonography. Dr. Luis’ principal clinical and research interests include the use of echocardiography and multimodality cardiac imaging in the investigation, management and prognostication of patients with carcinoid heart disease. His other clinical and research interests include cardio-oncology, valvular heart disease and pericardial diseases. THANKS TO OUR SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

Join NCF for NCD2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page WATCH THE RECORDING Celebrate NET Cancer Day at the LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 3:30 pm. ABOUT Hear presentations from local NET experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Show how you live well with Neuroendocrine Cancer in our "Show & Tell" Video Slideshow (will be played during our reception). Post-Event Ice Cream Social There is no cost to attend. This event is made possible by the generosity of donors and sponsors. This event will not be broadcast. LOCATION Santa Monica Bay Woman's Club 1210 4th St, Santa Monica, CA 90401 Parking will be fully validated at SP+ Parking Garage Structure 1 at 1234 4th St, Santa Monica, CA. AGENDA *Subject to change. Please check back closer to the event for the most accurate agenda. Time Topic Speaker 8:30 - 9 AM Registration & Breakfast 9 - 9:10 AM Welcome LACNETS Team 9:10 - 9:20 AM A NET Impact Story A NET Patient 9:20 - 9:35 AM A NET Surgeon's Perspective on What to Ask Your Surgeon & How to Prepare for Surgery Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai 9:35 - 9:50 AM Alpha vs Beta PRRT: Which is for me? Martin Auerbach, MD, Nuclear Medicine, UCLA 9:50 - 10:20 AM Q&A Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai & Martin Auerbach, MD, Nuclear Medicine, UCLA 10:20 - 10:50 AM Break 10:50 - 10:55 AM A NET Impact Story A NET Caregiver 10:55 - 11:15 AM The Latest in NET Medical Therapies Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai 11:15 - 11:35 AM The Endocrine in Neuroendocrine Run Yu, MD, Endocrinologist, UCLA 11:35 - 11:50 AM Liver Directed Therapy for Neuroendocrine Liver Tumors H. Gabriel Lipshutz MD, Interventional Radiologist, Cedars-Sinai 11:50 AM - 12:30 PM Q&A All Faculty (Moderated by Lisa Yen) 12:30 - 1:30 PM Lunch & Networking 1:30 - 2:05 PM The Future of NETs: Evolving Treatments & Clinical Trials Jaydira Del Rivero, MD, Medical Oncologist, Endocrinologist, National Cancer Institute, National Institutes of Health 2:05 - 2:25 PM Spreading Awareness Globally: INCA's Think NENs Stephanie Alband, INCA President & PPA Executive Director 2:25 - 2:35 PM Let's Talk About NETs: How YOU Can Spread Awareness Heather Davis, LACNETS Associate Director of Advocacy & Outreach 2:35 - 3:00 PM Music Heals Drum Healing with John Fitzgerald 3:05 - 3:15 PM Closing LACNETS Team 3:15 - 4:30 PM Networking Reception with Show & Tell Slideshow MODERATORS : Andrew Hendifar, MD, & Lisa Yen, Director of Programs and Outreach SPEAKERS: ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. MARTIN AUERBACH, MD Nuclear Medicine, UCLA Dr. Allen-Auerbach is the Medical Director of UCLA Nuclear Medicine and Clinical Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes and as well as applications of Nuclear Medicine for the treatment of cancer. RUN YU, MD, PhD Endocrinologist, UCLA Run Yu, MD, PhD, received his MD degree from Peking Union Medical College in Beijing and his PhD degree in pharmacology from University of Rochester in New York. Dr. Yu completed an endocrine research fellowship, an internal medicine residency, and a clinical endocrinology fellowship at Cedars-Sinai Medical Center. Dr. Yu’s clinical and research interests include diabetes, thyroid, and endocrine tumors and syndromes. Dr. Yu enjoys describing novel clinical findings in endocrinology. H. GABRIEL LIPSHUTZ, MD Interventional Radiologist Cedars-Sinai Medical Center H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. JAYDIRA DEL RIVERO, MD Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. STEPHANIE ALBAND, MSBA Board President, INCA Executive Director, The Pheo Para Alliance Stephanie Alband, MSBA, joined Pheo Para Alliance in March of 2019. She has over 20 years of experience in the nonprofit industry, with ten years working exclusively for rare disease organizations, including the Huntington’s Disease Society of America and Angioma Alliance. Her experience with her daughter’s rare cancer has helped her better understand and successfully navigate the unique challenges faced by the rare disease community. She currently serves as the President for the International Neuroendocrine Cancer Alliance (INCA) and previously served as Communications Chair and a Member of the Board of Directors. JOHN FITZGERALD Drum Circle Facilitator & Coach Rhythm With a Purpose Before he fell in love with the transformational impact of coaching, and rhythm facilitation, John spent decades as a degreed percussionist performing jazz and classical music, and the amazing music of cultures from around the world. Rhythms, cycles, and improvisation have always been central to his joy and passion, the spontaneous personal expression that is such a vital part of all living cultures, and indeed, all our lives. As the Manager of Recreational Music Activities for Remo Inc., for 23 years, he created relationships with organizations and individuals, educating and advocating for the use of music for wellbeing in every imaginable population through a global network of partnerships, facilitators, and Remo’s distributor network. Presentations, training, and facilitated experiential activities at conferences and symposia were a central part of his work at Remo, and his passion as well. In addition to one on one work with individuals and organizational leaders, John designed and facilitated team-building, communication and leadership workshops for over 20 years. If you are newly diagnosed, or need a refresher on NET terms and basics, we encourage you to watch Dr. Aman Chauhan’s presentation “NETS 101: Overview of NET Terms & Concepts " or Dr. Chandrasekharan’s presentation “Understanding NET Diagnosis.” The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Lu-177 DOTATATE + Triapine in GEP-NETs << Back Phase 2 Trial: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors DRUG/TREATMENT: LUTATHERA (Lu-177) + Triapine CLINICALTRIALS.GOV IDENTIFIER: NCT05724108 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=ptDSlj3Neao June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study https://www.youtube.com/watch?v=rK0NSdorBnk April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study DESCRIPTION: This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aman Chauhan, MD EMAIL: axc3268@med.miami.edu RELATED RESOURCES Clinical Trials Using Lutetium Lu 177 Dotatate - NCI Dr. Chauhan's presentation slides can be downloaded here: Dr. Chauhan Presentation on Lu-177 DOTATATE + Triapine Trial .pptx Download PPTX • 16.18MB 2023 NANETS Abstract shows the combination of Triapine and Lu-177 DOTATATE was safe with preliminary efficacy signals.

Join NCF for Feb2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=wgEoFAQ7lp8 ABOUT Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. ABOUT DR. PEREZ Kim Perez, MD Medical Oncologist D ana Farber Cancer Institute (DFCI) Dr. Kimberly Perez, MD is a member of the Dana-Farber Cancer Institute/Harvard Cancer Center Gastrointestinal Oncology and Cancer Genetics and Prevention disease centers. She is a Senior Physician in Medical Oncology at Dana-Farber Cancer Institute, an Associate Physician in Medical Oncology at Brigham and Women’s Hospital, co-Director of the DFCI Gastrointestinal Clinical Trials program, and an Assistant Professor of Medicine at Harvard Medical School. She received her undergraduate training at Georgetown University in Washington DC and received her medical doctorate from George Washington University in Washington DC. She completed her residency and fellowship training at Rhode Island Hospital in 2010. After completing her fellowship, she joined the medical faculty at Warren Alpert School of Medicine at Brown University and served as a Gastrointestinal Oncologist at the Comprehensive Cancer Center at Rhode Island Hospital. She joined the faculty at the Dana-Farber Cancer Institute in 2015 as a medical oncology physician-scientist who provides patient care and conducts clinical research of novel therapies for patients diagnosed with gastrointestinal cancers and inherited cancer syndromes. Since she joined the faculty, she was designated a Hale Family Center for Pancreatic Cancer Research Clinical Investigator and has developed and led investigator-initiated bench to clinic multi-institutional clinical trials for patients with pancreatic adenocarcinoma. Within the Neuroendocrine and Carcinoid program, she has led multi-institutional clinical trials, translational efforts, and served and led national therapeutic guideline efforts. Dr. Perez is a medical oncology physician-scientist who provides patient care and conducts clinical research of novel therapies for patients diagnosed with gastrointestinal cancers and associated hereditary cancer syndromes. Since she joined the faculty at Harvard Medical School and the Dana-Farber Cancer Institute in 2015, she has developed and led investigator-initiated clinical trials investigating novel therapies for patients with pancreatic adenocarcinoma and neuroendocrine tumors. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) << Back Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) CLINICALTRIALS.GOV IDENTIFIER: NCT05997056 DRUG/TREATMENT: IV PHASE: 2 STATUS: Recruiting SPONSOR: Aadi Bioscience, Inc. DESCRIPTION: https://www.youtube.com/watch?v=DbA55lS1dhk Dr. Scott Paulson Discusses the Nab-sirolimus Trial This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aadi Bioscience Medical Information EMAIL: MedInfo@aadibio.com PHONE: 1-888-246-2234 Locations: Recruiting: United States at Texas Oncology in Dallas, Texas 75246 Contact: Christine Terraciano at christine.terraciano@usoncology.com Principal Investigator: Scott Paulson, MD Recruiting: United States at Hoag Memorial Hospital Presbyterian in Newport Beach, California 92663 Contact: Jason Ledesma at jason.ledesma@hoag.org Principal investigator: Michael Demeure, MD Not Yet Recruiting: United States, Denver, Colorado 80218